Figure e-2. MRZ and herpesvirus-specific antibodies in CSF and serum before (V0) and after 12 months of natalizumab treatment (V12). Serum and CSF levels of antibodies reactive to (A) measles virus, (B) rubella virus, (C) VZV, (D) CMV, (E) HSV-1, (F) HSV-2, (G) EBV-VCA and (H) EBV-EBNA-1 are depicted in arbitrary units (AU). Intrathecal production of the respective antibodies is indicated by CSF/serum antigen-specific antibody index (CAI\text{Measles}, CAI\text{Rubella}, CAI\text{VZV}, CAI\text{HSV-1}, CAI\text{HSV-2}, CAI\text{CMV}, CAI\text{EBV-VCA}, CAI\text{EBNA-1}). The p-value is shown in case of statistically significant differences. Statistics: Wilcoxon-matched pairs test (A-H).